Imunon (IMNN) chair receives stock grant and updates IRA holdings

Q: Was the Imunon (IMNN) Form 4 transaction a stock grant or a market purchase?

The Form 4 shows a stock grant , not a market purchase. Michael H. Tardugno received 4,089 shares of Imunon common stock at $2.06 per share as compensation in lieu of cash base salary, which is classified as a grant or award acquisition.

Q: Did Michael H. Tardugno sell any Imunon (IMNN) shares in this Form 4 filing?

The filing does not report any sales of Imunon shares. It shows a grant of 4,089 shares as compensation and an update that 4,622 shares are now held indirectly in an IRA following a rollover from a 401(k) plan.

Q: What is the significance of the IRA and 401(k) rollover in the Imunon (IMNN) Form 4?

The Form 4 notes that 4,622 shares of Imunon common stock are held indirectly in an IRA after being rolled over from a 401(k) Plan . This represents a change in how the shares are held, rather than a new purchase or sale in the market.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. Executive Chairman of the Board Michael H. Tardugno reported a routine equity compensation grant and an update to his indirect holdings. He received 4,089 shares of common stock at $2.06 per share, granted in lieu of cash for base salary, bringing his direct holdings to 12,838 shares. A separate entry shows 4,622 shares of common stock held indirectly in an IRA after shares were rolled over from a 401(k) plan. The filing shows no open-market purchases or sales and no derivative positions.

Insider Trade Summary

Net Buyer: 4,089 shares

Net Buy 2 txns

Insider Tardugno Michael H

Role Executive Chairman of Board

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,089	$2.06	$8K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 12,838 shares (Direct); Common Stock — 4,622 shares (Indirect, Held by IRA)

Footnotes (2)

F1. Stock granted in lieu of cash for base salary
F2. Shares were rolled over from 401(k) Plan

Key Figures

Stock grant: 4,089 shares at $2.06 Direct holdings after grant: 12,838 shares IRA holdings: 4,622 shares

3 metrics

Stock grant 4,089 shares at $2.06 Common stock granted in lieu of cash base salary

Direct holdings after grant 12,838 shares Common stock directly held after grant

IRA holdings 4,622 shares Common stock held indirectly in IRA after 401(k) rollover

Key Terms

Grant, award, or other acquisition, IRA, 401(k) Plan, Executive Chairman of Board

4 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

IRA financial

"nature_of_ownership: Held by IRA"

An individual retirement account (IRA) is a savings account designed to help people put aside money for their retirement, often with tax advantages that encourage long-term savings. It matters to investors because it can grow over time, providing financial security later in life, and offers benefits that can reduce current taxes or allow investments to compound more effectively.

401(k) Plan financial

"Footnote: Shares were rolled over from 401(k) Plan"

A 401(k) plan is a workplace retirement account that lets employees set aside part of their pay into a tax-advantaged savings pot, often with employers adding matching contributions — like a workplace piggy bank for future income. It matters to investors because the amount people save and how employers fund these plans influence consumer spending, corporate payroll costs and the flow of money into financial markets, which can affect stock prices and company valuations.

Executive Chairman of Board financial

"officer_title: Executive Chairman of Board"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/09/2026 - 05:16 PM Accepted by SEC EDGAR 06/09/2026 - 05:15 PM

FAQ

What insider transaction did Imunon (IMNN) report for Michael H. Tardugno?

Imunon reported that Executive Chairman Michael H. Tardugno received 4,089 shares of common stock as a stock grant in lieu of cash base salary at $2.06 per share. The Form 4 also updated his indirect IRA holdings without any reported open-market trades.

How many Imunon (IMNN) shares does Michael H. Tardugno hold after this Form 4?

After the reported transactions, Michael H. Tardugno directly holds 12,838 shares of Imunon common stock. In addition, an IRA associated with him holds 4,622 shares, reflecting a rollover from a 401(k) plan rather than a market purchase or sale.

Was the Imunon (IMNN) Form 4 transaction a stock grant or a market purchase?

The Form 4 shows a stock grant, not a market purchase. Michael H. Tardugno received 4,089 shares of Imunon common stock at $2.06 per share as compensation in lieu of cash base salary, which is classified as a grant or award acquisition.

Did Michael H. Tardugno sell any Imunon (IMNN) shares in this Form 4 filing?

The filing does not report any sales of Imunon shares. It shows a grant of 4,089 shares as compensation and an update that 4,622 shares are now held indirectly in an IRA following a rollover from a 401(k) plan.

What is the significance of the IRA and 401(k) rollover in the Imunon (IMNN) Form 4?

The Form 4 notes that 4,622 shares of Imunon common stock are held indirectly in an IRA after being rolled over from a 401(k) Plan. This represents a change in how the shares are held, rather than a new purchase or sale in the market.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tardugno Michael H

(Last)

(First)

(Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE

NEW JERSEY

08648

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Executive Chairman of Board

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/05/2026		A		4,089⁽¹⁾	A	$2.06	12,838	D
Common Stock								4,622⁽²⁾	I	Held by IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Stock granted in lieu of cash for base salary

2. Shares were rolled over from 401(k) Plan

	/s/ Susan Eylward, Attorney-in-Fact for Michael Tardugno	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR